Setting 
My Cart
Toggle Nav
Close
  • Menu
  • Setting

Bortezomib (PS-341)

Catalog No.
A2614
proteasome inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$72.00
In stock
Evaluation Sample
$30.00
In stock
10mg
$66.00
In stock
25mg
$119.00
In stock
100mg
$275.00
In stock
500mg
$748.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Bortezomib (PS-341; CAS 179324-69-7) is a reversible proteasome inhibitor structurally composed as an N-terminally protected dipeptide (Pyz-Phe-boroLeu) containing pyrazinoic acid, phenylalanine, and leucine with boronic acid substitution. It exerts biological activity primarily by inhibiting proteasomal degradation pathways, thereby accumulating pro-apoptotic factors and initiating programmed cell death. Bortezomib inhibits proliferation in cell-based assays, such as human non-small cell lung cancer H460 cells (IC50 = 0.1 µM). It has clinical approval for relapsed multiple myeloma and mantle cell lymphoma, and is widely employed in research to study proteasome-regulated cellular processes and apoptosis signaling pathways.

References:
1. Takimoto CH, Calvo E. "Principles of Oncologic Pharmacotherapy" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
2. Gelman JS, Sironi J, Berezniuk I, Dasgupta S, Castro LM, Gozzo FC, Ferro ES, Fricker LD (2013). "Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib". In Gartel, Andrei L. PLoS One 8 (8): e53263.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt384.24
Cas No.179324-69-7
FormulaC19H25BN4O4
SynonymsBortezomib,PS-341,LDP-341,MLM341,MG-341,NSC-681239
Solubilityinsoluble in EtOH; insoluble in H2O; ≥19.21 mg/mL in DMSO
Chemical Name[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
SDFDownload SDF
Canonical SMILESB(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1]:

Cell lines

Canine malignant melanoma cell lines (CMM-1, CMM-2, ChMC, KMeC, LMeC, OMJ, OMS, OMK, and NML

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

72h; IC50=3.5~5.6 nM (nine kinds of cells)

Applications

Bortezomib potently suppressed the growth in 21 drugs, while other compounds had no or minimal effect on cell growth. We thus focused on bortezomib and examined its growth inhibitory properties against nine canine malignant melanoma cell lines (CMM-1, CMM-2, ChMC, KMeC, LMeC, OMJ, OMS, OMK, and NML). Bortezomib inhibited the growth of all cell lines with calculated IC50 values of 3.5~5.6 nM.

Animal experiment [1]:

Animal models

Nude athymic mice

Dosage form

0.8 mg/kg; intravenous injection

Applications

The in vivo growth inhibitory activity of bortezomib against CMM-1 cells was evaluated using a xenograft mouse model. Bortezomib significantly suppressed the growth of tumours after Day 4 of treatment (P < 0.01, control vs. bortezomib). Tumours from the bortezomib-treated mice showed a significant decrease in mitotic index compared to controls (P

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Ito K, Kobayashi M, Kuroki S, et al. The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo[J]. The Veterinary Journal, 2013, 198(3): 577-582.

Biological Activity

Description Bortezomib (PS-341) is a potent inhibitor of 20S proteasome with Ki of 0.6 nM.
Targets 20S proteasome          
IC50 0.6 nM (Ki)          

Quality Control

Chemical structure

PS341

Related Biological Data

PS341

Related Biological Data

PS341

Related Biological Data

PS341

Related Biological Data

PS341

Related Biological Data

PS341

Related Biological Data

PS341

Related Biological Data

PS341